Cargando…
Hyperamylasemia is not Associated with Dipeptidyl Peptidase 4 Inhibitors in South Indian Adults with Type 2 Diabetes Mellitus
INTRODUCTION: Although not definitive, there is small increased risk of acute pancreatitis with the use of dipeptidyl peptidase 4 inhibitors (DPP4i). Hence, there is an interest in the elevation of pancreatic enzymes among type 2 diabetes mellitus (T2DM) patients using DPP4i. However, the studies re...
Autores principales: | Sarathi, Vijaya, Tirupati, Sunanda, Sabinkar, Gayatri, Mohan, Rama |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443446/ https://www.ncbi.nlm.nih.gov/pubmed/37614844 http://dx.doi.org/10.4103/ijabmr.ijabmr_503_22 |
Ejemplares similares
-
SUN-389 Consequences of Late Diagnosis of 11β-Hydroxylase Deficiency
por: Sabinkar, Gayatri, et al.
Publicado: (2019) -
New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022) -
Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects
por: Yanagimachi, Tsuyoshi, et al.
Publicado: (2016) -
Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies
por: Patoulias, Dimitrios, et al.
Publicado: (2021) -
Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus
por: Dave, Darshan J.
Publicado: (2011)